Zolasta 4 mg Injection
Zolasta 4 mg Injection Zolasta contains Zoledronic Acid, a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption. It selectively binds to bone mineral matrix and blocks farnesyl pyrophosphate (FPP) synthase in osteoclasts, leading to their inactivation and apoptosis. This reduces bone turnover, prevents skeletal-related events (such as pathological fractures and spinal cord compression), and lowers elevated serum calcium concentrations. It is indicated for the treatment of hypercalcemia of malignancy, bone metastases from solid tumors, multiple myeloma, and osteoporosis.
| Brand | Zolasta |
| Storage Temperature | Store below 30°C in a dry place, protected from light and moisture |
| Prescription Needed | Yes |
| Composition | Zoledronic Acid |
| Strength | 4 mg |
| Form | Sterile Lyophilized Powder for Injection |
| Pack Size | 1 Vial |
| Packaging | Single-dose vial |
| Country of Origin | Made In India |
| Manufacturer | Intas Pharmaceuticals Ltd. |
Zolasta 4 mg Injection
Zolasta 4 mg Injection Zolasta contains Zoledronic Acid, a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption. It selectively binds to bone mineral matrix and blocks farnesyl pyrophosphate (FPP) synthase in osteoclasts, leading to their inactivation and apoptosis. This reduces bone turnover, prevents skeletal-related events (such as pathological fractures and spinal cord compression), and lowers elevated serum calcium concentrations. It is indicated for the treatment of hypercalcemia of malignancy, bone metastases from solid tumors, multiple myeloma, and osteoporosis.
